Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

CSE:AGN - Post Discussion

View:
Post by NamesJeb on Dec 15, 2020 8:22am

Data

https://www.globenewswire.com/news-release/2020/12/15/2145345/0/en/Algernon-Pharmaceuticals-Announces-Positive-Trending-Interim-Data-for-its-Phase-2b-3-Ifenprodil-COVID-Study.html
Comment by NamesJeb on Dec 15, 2020 8:30am
"(the Company or Algernon) a clinical stage pharmaceutical development company, is pleased to report, in a descriptive format, positive trending interim data for the Phase 2b part of the Companys Phase 2b/3 clinical study of Ifenprodil for COVID-19."
Comment by SnoopDOdoubleG on Dec 15, 2020 8:42am
Emergency FDA approval based on the reduction of days in hospital will be extremely good for AGN and we shareholders. The Data set is very positive which will help us get to a new baseline until that happens. Patience is key....GLTA
Comment by Biofinanace on Dec 15, 2020 8:56am
AGN becomes first Canadian company to share positive outcome from a covid therapeutic trial.  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities